NEKTAR THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.76 USD | +10.00% |
|
+12.10% | +211.50% |
| May. 09 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M | MT |
| May. 09 | Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024 |
Presenter SpeechChris Shibutani (Analysts)Welcome, everyone, to the afternoon start for the 44...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the bodyâs immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the bodyâs innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
Sector
Pharmaceuticals
Calendar
2024-06-05
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1.76
USD
Average target price
1.6
USD
Spread / Average Target
-9.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +211.50% | 323M | |
| +30.38% | 684B | |
| +28.99% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.06% | 240B | |
| +9.31% | 208B | |
| -7.36% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Transcript : Nektar Therapeutics Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 01